drugset
Drugs / IMM-101
last change Dec 2025 re-read 2 minutes ago

IMM-101

Other / unclassified

Developed for
melanoma · malignant pancreatic neoplasm · cancer · colorectal cancer · COVID-19 · malignant exocrine pancreas neoplasm · metastatic malignant neoplasm
Investigated by
Immodulon Therapeutics Ltd · AIO-Studien-gGmbH · ATGen Canada Inc · BioCan Rx · Canadian Cancer Society (CCS) · Canadian Cancer Trials Group
+9 more · Canadian Centre for Applied Research in Cancer Control (ARCC) · HCA International Limited · Impatients N.V. trading as myTomorrows · Karen Carty · NHS Greater Glasgow and Clyde · Ontario Institute for Cancer Research · Roche Pharma AG · Theradex · University of Glasgow

Trials 9 · a red edge is where a trial was stopped

today NCT06498518 · Ph 2 NCT05118724 · Ph 2 NCT04442048 · Ph 3 NCT03711188 · Ph 2 NCT03009058 · Ph 1/2 NCT01559818 · Ph 1/2 NCT01303172 · Ph 2 NCT01308762 · Ph 1
201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT01308762 Mar → Sep 2010 melanoma Immodulon Therapeutics Ltd Completed No outcome recorded
Phase 1/22 trials
Phase 1/2 NCT03009058 May → Aug 2017 metastatic malignant neoplasm Immodulon Therapeutics Ltd Terminated No outcome recorded
Phase 1/2 NCT01559818 Feb 2012 → Jul 2019 melanoma Immodulon Therapeutics Ltd Terminated No outcome recorded
Phase 24 trials
Phase 2 NCT06498518 Jun 2024 → May 2025 malignant pancreatic neoplasm Karen Carty Withdrawn No outcome recorded
Phase 2 NCT05118724 Dec 2021 → Apr 2027 expected colorectal cancer AIO-Studien-gGmbH Active not recruiting No outcome recorded
Phase 2 NCT03711188 Oct 2018 → Dec 2021 melanoma Immodulon Therapeutics Ltd Completed No outcome recorded
Phase 2 NCT01303172 Jun 2011 → Jun 2014 malignant pancreatic neoplasm Immodulon Therapeutics Ltd Completed No outcome recorded
Phase 31 trial
Phase 3 NCT04442048 Oct 2020 → May 2024 COVID-19, cancer Canadian Cancer Trials Group Completed No outcome recorded
Phase not stated1 trial
— NCT04137822 — malignant exocrine pancreas neoplasm Impatients N.V. trading as myTomorrows No longer available No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 9 sources stand behind the page.

FieldValueCited text
Known as IMM-101 ClinicalTrials.gov intervention name — accepted as the source's own label NCT05118724 ↗
8

NCT06498518 ↗

NCT03711188 ↗

NCT01303172 ↗

NCT04442048 ↗

NCT04137822 ↗

NCT01559818 ↗

NCT01308762 ↗

NCT03009058 ↗
Modality Other / unclassified “IMM-101 is a suspension of heat-killed whole cell M. obuense in borate-buffered saline.” NCT01303172 ↗
Route Other “A single 0.1 mL intradermal injection of IMM-101 (10 mg/mL) will be administered every 2 weeks” NCT01303172 ↗